Patients treated with ALIMTA and cisplatin required fewer transfusions (16.4% versus 28.9%, p < 0.001), red blood cell transfusions (16.1% versus 27.3%, p < 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
I pazienti trattati con ALIMTA e cisplatino hanno richiesto un minor numero di trasfusioni (16,4% verso 28,9%, p < 0.001), trasfusioni di globuli rossi (16,1% verso 27,3%, p < 0.001) e trasfusioni di piastrine (1,8% verso 4,5%, p = 0.002).